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Abstract: Fracture of the hip is frequently a catastrophic event in the elderly, often resulting 
in death within a year and of the survivors, few regain pre-fracture quality of life. Although less 
appreciated, fractures of the spine result in signiﬁ  cant morbidity and are also associated with 
increased mortality compared with individuals without a fracture. In recent years there has been 
an explosion in the development of new drugs for the treatment of osteoporosis. Recombinant 
human parathyroid hormone (1–34) (20 μg/day) is a recent addition to this armamentarium with 
a novel mechanism of action, which was approved by the US FDA for the treatment of post-
menopausal osteoporosis and male osteoporosis secondary to hypogonadism in November 2002. 
It is the ﬁ  rst osteoporosis treatment that leads to the formation of new bone with architecture 
similar to normal bone. Intense efforts have been made to understand the effect of teriparatide 
on antiresorptive therapy and vice versa. Although these relationships are not completely 
understood, the results of recent studies allow clinicians to begin to optimize therapeutic gains 
in bone mineral density and improve anti-fracture efﬁ  cacy.
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Introduction
There are more than 1.5 million fractures each year that are attributed to osteoporosis 
in America at a cost of US$14 billion to the US health care system (NOF 2007). One 
in two women and one in four men over the age of 50 will suffer a fracture related to 
osteoporosis (NOF 2007), with absolute risk of fracture increasing two fold for each 
decade of life (Siris et al 2006). While fractures of the hip and vertebrae are most 
frequently sited, non-hip, and non-vertebral fractures account for a signiﬁ  cant propor-
tion of fractures and are also associated with signiﬁ  cant morbidity (Delmas et al 2007). 
Over 20% of persons aged 50 and older with hip fracture die within the ﬁ  rst year. Death 
rates are higher in men, often exceeding 30%, and increase with advancing age (Cauley 
et al 2000). Hip fracture leads to loss of functional independence, with approximately 
one-third of previously independent individuals requiring nursing home placement, 
and at 6 months, only 15% regain ambulatory status without an assistive device (NOF 
2007). Up to 60% of individuals will require some assistance a year later (IOF 2007). 
Vertebral fractures account for approximately 45% of osteoporosis-related fractures, 
and have signiﬁ  cant immediate and long-term complications such as pain, respira-
tory complications, loss of height, and loss of quality of life. Of those presenting with 
vertebral fractures, the risk of new vertebral and non-vertebral fracture increases 4- to 
5-fold (Klotzbuecher et al 2000). Moreover, there is mounting evidence that vertebral 
fractures also increase mortality within 1 year of the fracture and this excess risk 
increases with time (Cooper et al 1993; Center et al 1999; Cauley et al 2000). Clearly 
osteoporosis is a major public health concern with signiﬁ  cant health care expenditures 
and personal burden. As the baby boomers enter retirement age, the percentage of elder 
adults will increase. The burden of osteoporosis related fractures is projected to reach 
over 3 million fractures per year with substantial increases in health care expenditures 
estimated at over US$25.3 billion per year (Burge et al 2007).Clinical Interventions in Aging 2007:2(4) 500
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Fracture risk
Although great strides have been made in identifying and 
treating individuals with osteoporosis, osteoporosis related 
fractures remain a major public health problem. Osteoporosis 
related fractures occur with little or no trauma and are often 
called fragility fractures. Up to 40% of white women and 
13% of white men in the US will suffer at least one fragility 
fracture in their lifetime (IOF 2007; NOF 2007). Although 
low bone mineral density (BMD) is highly predictive of 
an increased risk of future fracture (WHO 1994), multiple 
factors are involved in estimating an individual’s risk includ-
ing age, race, previous fracture, glucocorticoid use, gender, 
history of falling, hyperparathyroidism, and malabsorption 
syndromes. It is important to recognize these risk factors, for 
they can have a profound effect on the estimation of overall 
risk. For instance whites have twice the fracture risk of 
Asians and blacks (Barrett-Connor et al 2005), and women 
have almost twice the rate of fracture as men at any site 
(van Staa et al 2001). The risk of a second vertebral fracture 
in an individual with a previous vertebral fracture is at least 
4-fold (Klotzbuecher et al 2000) and the risk of hip fracture 
is doubled compared with those fracture free (Kanis et al 
2004). Despite this clear predictor of increased risk, only 
one-third of all vertebral fractures noted on radiographs come 
to medical attention (Cooper et al 1992). Age is a strong risk 
factor independent of BMD, with a 70-year-old female hav-
ing double the risk of fracture compared with a 50-year-old 
female with the same BMD (Kanis et al 2004). Frailty is also 
an independent risk factor; individuals with a high fall risk 
and low BMD were at least 4-fold more likely to fracture 
than women without low BMD or falls (Dargent-Molina et al 
1996). These and other studies indicate that BMD is crucial 
in the evaluation for osteoporosis as an initial step, but other 
risk factors must be identiﬁ  ed that may modify treatment or 
change the decision to treat. For instance, a vertebral fragility 
fracture indicates a high risk of future fracture regardless of 
BMD and therapy is indicated.
Mechanism of action
Osteoporosis develops when there is an imbalance between 
bone formation and bone resorption. In states of high turn-
over, such as sex steroid deﬁ  ciency, rheumatoid arthritis, 
and certain malignancies, resorption occurs in excess of 
formation. Antiresorptive agents such as estrogen, raloxifene, 
bisphosphonates, and calcitonin inhibit both aspects of 
bone remodeling, but slow resorption more than formation. 
Teriparatide is the ﬁ  rst approved anabolic, or bone building 
drug, where bone formation is stimulated more than 
resorption. To clinicians this seems counterintuitive, because 
the elevated levels of parathyroid hormone (PTH) found in 
hyperparathyroidism typically result in reduced BMD and 
increased fracture risk. Research has shown that bone forma-
tion occurs soon after PTH is administered because osteoblast 
formation is increased and osteoblast apoptosis is inhibited, 
which results in an increase in bone turnover and formation 
(Lindsay et al 1997).
Therefore, intermittent administration increases the 
number of bone forming osteoblasts whereas continuous 
administration increases the number of bone resorbing 
osteoclasts (Dobnig et al 2005). Overall there is a net increase 
in bone with each PTH cycle (Dobnig and Turner 1997; 
Hagino et al 2001). Importantly, the bone formed is “good” 
bone with histomorphometry and peripheral quantitative CT 
(pqCT) showing an increase in trabecular width and number 
(Figure 1), structurally similar to bone from younger indi-
viduals (Jiang et al 2003). This remodeling predominantly 
occurs at bone surfaces subject to mechanical stress (Hagino 
et al 2001; Hodsman et al 2005).
Clinical response to teriparatide
as single therapy
The largest number of teriparatide treated patients was 
examined in a phase III clinical trial published in 2001 
(Neer et al 2001). Over 1600 postmenopausal women with 
prior vertebral fractures were randomized to receive placebo 
or 20 μg or 40 μg of teriparatide for a median of 21 months. 
Compared with placebo, teriparatide increased BMD at the 
lumbar spine by 9% and 13%, respectively, and at the femoral 
neck by 2% to 5% over placebo (p   0.001). More impor-
tantly, the reduction in new vertebral fractures compared with 
control was highly signiﬁ  cant and similar between the two 
doses (65% and 69% respectively, p   0.001) (Figure 2). 
The reduction in the subset of vertebral fractures judged to 
be moderate to severe by radiologic criteria was even more 
pronounced, approximately 90% in both treatment groups 
(Figure 2). Fragility fractures at nonvertebral sites such as the 
hip and wrist were reduced by 53% (p   0.05). This study 
represents the effect of teriparatide alone, for the number of 
osteoporosis treatment-naive patients were similar between 
the placebo and treatment groups (85% vs 86%) and sub-
jects with prior osteoporosis treatment were off therapy for 
at least 2 months prior to randomization. BMD at the wrist 
was reduced slightly in the teriparatide group compared with 
controls; however, fracture risk was halved. This decrease 
in BMD has been noted in other, smaller studies (Body et al 
2002; Orwoll et al 2003; Kurland et al 2004). The explanation Clinical Interventions in Aging 2007:2(4) 501
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for the discrepancy between decrease in BMD and decrease 
in fracture risk at the wrist is unclear. One explanation may 
be that increased cortical deposition and remodeling result in 
decreased bone density but increased bone diameter resulting 
in greater bone strength.
A comparison between the effects of teriparatide and 
other treatments on new vertebral fractures and nonvertebral 
fractures is shown in Table 1. Although teriparatide decreased 
fractures at both vertebral and non-vertebral sites more than 
most other treatments, these are not head-to-head studies of 
these agents. Direct comparisons cannot be made because 
of differences in study design and patient populations. 
Nonetheless, the data show that teriparatide is at least as 
efﬁ  cacious as other accepted therapies for osteoporosis.
Whom should be treated?
Much of the recent research into teriparatide has involved 
examining the effects of other osteoporosis therapies on 
the response to teriparatide. From a clinical standpoint, this 
may have overly complicated the approach to teriparatide 
use, for the initial decision is who should be treated. A ﬁ  rst 
step in this process may be to consider whether the anabolic 
mechanism represented by teriparatide is inherently superior 
to the mechanism of antiresorptive therapy. In other words, 
in a perfect world where cost is not a consideration, should 
one class be chosen as first-line therapy over another? 
The deﬁ  nitive answer to this important question is not yet 
known, for there are insufﬁ  cient teriparatide follow-up 
data. However, from what we know as discussed above, 
anabolic agents make new bone with increased trabecular 
number and thickness. Antiresorptive agents inhibit bone 
remodeling and prevent further bone loss. Increases in 
BMD do occur with antiresorptives, but this occurs by the 
ﬁ  lling of resorptive cavities and prolonging mineralization, 
not from an improvement in the inherent structure of bone. 
In humans, bone histomorphometry, and quantitative CT 
(qCT) show increased trabecular width and number after 
teriparatide treatment, with these changes structurally similar 
to bone from younger individuals (Hodsman et al 2005). If 
teriparatide actually improves bone structure, then why in 
the Phase III study were there continued fractures in the 
teriparatide treated group? The study had a median follow-
up of 21 months from the initiation of therapy. The effects 
of teriparatide are not instantaneous and fractures would 
be expected early on while remodeling and advantageous 
changes in bone architecture occur.
Taken together, these considerations suggest that with the 
current clinical data and what we know of the mechanism of 
the two classes of drugs, anabolic therapy may be superior 
in some ways to antiresorptives. It should be stressed that 
there are no long-term clinical data at this time to support 
this conclusion, although for clinicians who ﬁ  nd these argu-
ments compelling, teriparatide appears to be an attractive 
ﬁ  rst-line drug in certain individuals. However cost, ease of 
administration, and side-effects are, as always, signiﬁ  cant 
considerations in the decision to treat. At the time of this 
writing, monthly treatment cost for teriparatide is approxi-
mately 3- to 4-fold that of bisphosphonates. Although not 
directly comparable, a cost-utility analysis performed in the 
UK between teriparatide, bisphosphonates, and raloxifene 
Figure 1 Teriparatide therapy improves skeletal architecture. Micro-CT scans of 
iliac crest biopsy specimens at baseline (A) and after 21 months of therapy (B) with 
teriparatide (20 μg/d). Reproduced with permission from Jiang Y, Zhao JJ, Mitlak BH 
et al 2003. Recombinant human parathyroid hormone (1–34) [teriparatide] improves 
both cortical and cancellous bone structure. J Bone Miner Res, 18:1932–41. Copyright 
© 2003 American Society for Bone and Mineral Research.
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showed that teriparatide treatment is justiﬁ  ed only in patients 
with a 4-fold risk of fracture above the age-controlled 
baseline risk (NICE 2004). Moreover, teriparatide must be 
injected subcutaneously, which some patients ﬁ  nd cumber-
some and difﬁ  cult. In terms of side-effects, as discussed 
in detail below, there are few side-effects associated with 
teriparatide treatment and subjects rarely withdrew from 
clinical trials.
It is important to stress that adequate calcium and vitamin D 
is crucial to ensure a good response to not only PTH, but 
other anti-osteoporosis agents. Abundant research suggests 
that up to 70% of the elderly suffer from hypovitaminosis D 
(Holick et al 2005; Mosekilde 2005). Agrawal et al studied 
the effectiveness of risedronate therapy in frail nursing 
home residents where 94% of the residents were vitamin D 
deﬁ  cient (Agrawal et al 2006). They demonstrated that the 
expected drop in biomarkers of formation or resorption was 
not observed. Likewise, a preliminary report showed that 
vitamin D deﬁ  ciency impaired the effect of alendronate in 
postmenopausal women (Ishijima et al 2005).
Teriparatide has been FDA approved for the treatment of 
patients at high risk of fracture, but assessing which patients 
Figure 2 Effect of teriparitide treatment (20 μg/d, black bar) compared with placebo (gey bar) on A. Risk of one or more new vertebral fracture. B. Risk of one or more 
new moderate or severe vertebral fractures.
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are at high risk is complex. Certainly patients over the age 
of 65 with markedly depressed T scores less than –3.5 fall 
into this category. This T score cutoff is somewhat arbitrary 
and the decision to treat elderly patients with teriparatide 
should also depend on other risk factors. Elderly patients 
with prior fragility fractures with BMD of T  2.5 should 
also be considered for treatment. Also, patients who continue 
to fracture or lose BMD after two years on bisphosphonate 
therapy would fall into the high risk category (Hodsman 
et al 2005). More controversial would be patients under the 
age of 60 and elderly with less severe osteoporosis. Also, 
patients who are immobile and non-weight bearing may 
not experience the expected gains from teriparatide since 
mechanical loading regulates PTH-stimulated gains in new 
bone (Troen 2006).
Another important factor is compliance. Compliance in 
many studies of anti-osteoporosis agents was excellent with 
a low dropout rate, but in practice, long-term compliance 
has been disappointing. Poor compliance may be attributed 
to poor patient-caregiver understanding, a low level of 
motivation, and the fact that osteoporosis is a “silent” disease 
with no obvious manifestation until a fracture occurs (Cramer 
et al 2006).
A recent study demonstrated that the response to PTH is 
the same in the elderly compared with younger individuals 
(Boonen et al 2006). Patients from the original Fracture 
Prevention Trial (Neer et al 2001) were separated into two 
subgroups with patient age younger than 75 and 75 and 
older. No difference was noted between the groups with 
regard to bone turnover markers, femoral neck BMD, ver-
tebral fractures, nonvertebral fragility fractures, height loss, 
hyperuricemia, or hypercalcemia.
Effect of other drug treatments
on teriparatide
Alendronate concurrently with PTH
The effect of previous or concurrent treatment with bisphos-
phonates on teriparatide is unclear. Two studies were 
Table 1 Therapeutic clinical trials evaluating fracture risk reduction in women with postmenopausal osteoporosis 
Trial  Dose  Mean  Treatment  Relative risk reduction (%)
   age  duration  (y)  vertebral  total  hip
        nonvertebral
Teriparatide
bNeer 20–40  μg/d 69  1.6  65  34
Risedronate
cVERT-NA 5  mg/d  69  1  65
     3  41  39
dVERT-MN 5  mg/d  71  1  61
     3  49  33  (NS)
eHIP 2.5–5  mg/d  74  3    20  40
Alendronate
fFIT 1  5–10 mg/d   71  3  47  20 (NS)  51
          2 1
gFIT 2  5–10 mg/d  68  4  44  12 (NS)  (NS)
Ibandronate
hBONE 2.5  mg/d 69  3  62  NS*
Raloxifene
iMORE 60  mg/d 67 3  30  NS
Hormone replacement
jWHI CEE  0.625         
 mg/d  plus  63  5.6 35  25  33
 progestin
kWHI CEE  0.625
 mg/d  63  6.8 38    39
Calcitonin
          5 0
lPROOF  200 IU/d  68  5  33  12 (NS)  (NS)
anot signiﬁ  cant; b(Neer et al 2001); c Vertebral Efﬁ  cacy With Risedronate Therapy North America (Harris et al 1999); d Vertebral Efﬁ  cacy With Risedronate Therapy Multinational 
(Reginster et al 2000); eHip Intervention Program (McClung et al 2001); fFracture Intervention Trial 1 (Black et al 1996); gFracture Intervention Trial 2 (Cummings et al 1998); 
hOral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (Chesnut et al 2004); iMultiple Outcomes of Raloxifene Evaluation (Ettinger et al 1999); 
j Women’s Health Initiative (Cauley et al 2003); k Women’s Health Initiative (Anderson et al 2004); lPrevent Recurrence of Osteoporotic Fractures (Chesnut et al 2000)Clinical Interventions in Aging 2007:2(4) 504
Bodenner et al
published concurrently in 2003 examining the effect of 
alendronate on PTH; one in postmenopausal women and 
one in elderly men with low bone density. In the ﬁ  rst study, 
238 postmenopausal women with T score less than –2.5 
or less than –2.0 with at least one additional risk factor 
of osteoporosis were randomized to daily full length PTH 
(1–84), alendronate (10 mg/d), or both and followed for 
12 months (Black et al 2003). The mean age of participants 
was 70 years in all groups and other clinical parameters 
were similar. No additive or synergistic effects on BMD 
were observed between the two therapies. The combination 
group showed BMD gains equal to but not greater than those 
obtained with PTH alone. Volumetric bone density using CT 
demonstrated a marked increase in the PTH alone group but 
combination therapy with PTH and alendronate was no dif-
ferent than alendronate alone. Biochemical markers of bone 
formation and resorption were depressed in the alendronate 
and combination group.
A similar study was conducted in 83 men with low BMD 
randomized to receive teriparatide (PTH 1–34), alendronate 
(10 mg daily) or both (Finkelstein et al 2003). In the com-
bination group, teriparatide was begun after 6 months of 
alendronate therapy. BMD was not signiﬁ  cantly different 
between alendronate and combination therapy at any site 
except the spine. PTH alone was superior to combination 
therapy at all sites except the total hip (p = 0.08). Biochemi-
cal markers of bone formation and resorption were markedly 
elevated in the PTH group, lower in the combination therapy 
group (p   0.01), and severely blunted in the alendronate 
alone group.
A third study examined the effect of daily teriparatide 
and treatment cycles of teriparatide administered every 
three months on elderly women with osteoporosis who had 
been taking alendronate for at least a year, and continued to 
take alendronate throughout the study (Cosman et al 2005). 
This study did not include a PTH alone group, so the effects 
of PTH on alendronate-treated patients cannot be directly 
assessed. The addition of PTH to alendronate resulted in 
signiﬁ  cant increases in spinal BMD in both the daily and 
cyclic group (6.1% and 5.4% respectively). Although signiﬁ  -
cant, these changes were less than that seen in most studies 
of PTH alone.
Taken together these studies demonstrate that with the 
bisphosphonate alendronate, combination with PTH results 
in increased bone turnover and BMD at the spine, but the 
increases are less than with PTH alone. There is no demon-
strable additive or synergistic effect between alendronate 
and PTH therapy when used together.
Alendronate before PTH
A smaller study examined 59 postmenopausal women with 
BMD T scores  –2.0 who had received either alendronate or 
raloxifene for 18–36 months prior to treatment with teripara-
tide for 18 months (Ettinger et al 2004). BMD responded in 
the raloxifene group as if subjects had received PTH alone. 
Patients pretreated with alendronate, however, showed no 
change in BMD after 6 months, and then a gradual rise in 
BMD was observed. There are several limitations to this 
study. The number of patients in each group was small, but 
most notably there were no control groups for the raloxifene 
and alendronate groups. Also, changes in BMD were 
compared to historical controls.
Alendronate following PTH
In an extension to the intact PTH study discussed above, 
the effect of alendronate administration after 1 year of PTH 
(1–84) treatment was evaluated in 119 osteoporotic elderly 
women (mean age of 70 years) randomized to placebo (PTH-
placebo) or alendronate at 10 mg/d (PTH-AL) for 1 additional 
year (Black et al 2005). The patient characteristics were again 
similar between the two groups with a mean age of 70, similar 
age at menopause, and similar BMD at the hip, spine and 
radius. Over the entire two year span of the study, increase in 
spinal BMD was much greater in the PTH-AL group (12.1%) 
than the PTH-control group (4.1%, p = 0.002). At the hip, 
PTH-AL was associated with a much larger increase in BMD 
than PTH-control (p   0.001). There was signiﬁ  cant loss 
of BMD at the wrist in both groups (p   0.001). Looking 
speciﬁ  cally at the second year of the study, PTH-AL gained 
BMD at the spine (4.9%) and the hip (3.6%) compared with 
the PTH-control group where there was loss of BMD at the 
spine (–1.7%) and no change at the hip. Markers of bone 
remodeling were elevated in the PTH-placebo and PTH-
alendronate group at 1 year, but both groups returned to 
baseline by 24 months.
These results suggest that alendronate therapy (and 
perhaps other bisphosphonates) administered after the 
recommended two year course of teriparatide would preserve 
and even extend the gains in BMD. This study was performed 
with the full-length PTH molecule but similar results would 
be expected with teriparatide.
Summary of teriparatide in combination 
with alendronate
Taken together, these studies suggest that alendronate therapy 
prior to, or concurrent with, PTH/teriparatide administration 
results in decreased bone remodeling and a blunted increase Clinical Interventions in Aging 2007:2(4) 505
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in BMD compared with PTH alone. This effect makes the 
timing of PTH initiation controversial. At least in one study, 
complete PTH effects on BMD are restored 6 months after 
alendronate has been discontinued (Ettinger et al 2004). 
Because teriparatide treatment is limited to 24 months in 
a patient’s lifetime, bisphosphonate could be discontinued 
for 6 months prior to initiating PTH therapy to maximize 
response during this rather short treatment period. It has 
recently been shown that a 6-month discontinuation of alen-
dronate therapy would not result in signiﬁ  cant loss of BMD 
or increase in fracture risk (Black et al 2006). Alternatively, 
immediately starting PTH will afford some, albeit reduced 
beneﬁ  t, and fracture risk may decrease sooner than increases 
in BMD secondary to beneﬁ  cial remodeling.
BMD falls off following discontinuation of PTH, and this 
decrease can be abrogated by alendronate therapy. After a 
2-year course of teriparatide, alendronate or other bisphos-
phonate therapy probably should be resumed.
There are several important caveats to these recommen-
dations. First and foremost, there are no data on changes in 
fracture risk after combination therapy with alendronate and 
PTH. All of these studies are based on BMD as a surrogate 
for efﬁ  cacy of therapy, and there is a poor correlation between 
the increase in BMD and decreased risk of fracture (Delmas 
and Seeman 2004). Second, intact PTH and teriparatide were 
used in these studies and their effects may not be interchange-
able. Also, alendronate was the only bisphosphonate used in 
these studies. The effect of other bisphosphonates on teripa-
ratide has not been examined. There are clear differences 
between bisphosphonates in terms of bone afﬁ  nity (Leu et al 
2006; Nancollas et al 2006). Perhaps other bisphosphonates 
may not blunt remodeling to the same degree as alendronate, 
with the possibility of concurrent bisphosphonate therapy 
or institution of PTH sooner after discontinuation of a 
bisphosphonate.
Combination therapy with raloxifene
and estrogen
Raloxifene is a selective estrogen receptor modulator (SERM) 
with estrogen-like properties at the skeleton and lipid system 
and anti-estrogen effects at the uterus and breast. Raloxi-
fene has anti-fracture efﬁ  cacy at the spine similar to other 
antiresorptives. For the purposes of the present discussion, 
estrogen and raloxifene will be discussed together. An early 
study in the mid 1990s examined postmenopausal women 
on HRT randomized to receive placebo or teriparatide for 3 
years. BMD steadily increased at the spine and hip reaching 
a maximum of 13% and 2.7% respectively (Lindsay et al 
1997). A later study by the same group examined 52 post-
menopausal women on HRT for at least 2 years that were 
again randomized to placebo vs teriparatide for 3 years. BMD 
at the spine increased 13.4% and at the hip 4.4%. Biochemical 
markers of bone formation were increased with teriparatide 
treatment compared with placebo, and BMD and markers 
of bone formation did not substantially decrease for up to 1 
year after discontinuation of teriparatide therapy (Cosman 
et al 2001).
The combination of raloxifene and teriparatide was 
examined as part of the comparison trial described above of 
59 postmenopausal women who had received either alen-
dronate or raloxifene for 18–36 months prior to treatment 
with teriparatide for 18 months (Ettinger et al 2004). There 
was an unimpeded and highly signiﬁ  cant increase in BMD 
in the group previously treated with raloxifene compared 
with baseline at the spine (10.2%, p   0.05) and the hip 
(1.8%, p   0.05).
In summary, it appears that prior or concurrent therapy 
with HRT or raloxifene does not inhibit the anabolic 
effects of PTH. These data suggest that addition of PTH 
will be beneﬁ  cial under these circumstances. However, it 
is not known whether the combination affords additive or 
synergistic beneﬁ  ts.
PTH and glucocorticoid-induced 
osteoporosis
Treatment with glucocorticoids rapidly causes a decrease in 
BMD and increased fracture risk (van Staa et al 2002). Both 
risedronate and alendronate have been shown to substantially 
decrease the risk of fractures in glucocorticoid-induced osteo-
porosis (GIO), and treatment with these agents has become 
standard of care (Saag et al 1998; Eastell et al 2000). These 
patients often have very low BMD by the time treatment is 
initiated, and the use of an anabolic agent to build new bone 
would be an attractive alternative to bisphosphonate therapy 
or anabolic treatment antecedent to initiating a bisphospho-
nate. To evaluate PTH treatment of glucocorticoid-treated 
patients, 51 osteoporotic (T   –2.5) postmenopausal women 
receiving 8.0 mg of prednisone per day (±3.78) and HRT 
were randomized to continued HRT and teriparatide for 
1 year or continued HRT alone (Lane et al 1998; Rehman 
et al 2003). The mean age was 65 years and patients had been 
on HRT for approximately 16 years. In the PTH/HRT group, 
BMD as measured by quantitative CT and by DEXA had 
increased 35% and 11% respectively compared with the HRT 
alone group where BMD had increased only 1.3% and 0.2%. 
A follow-up study for an additional year (24 months total) Clinical Interventions in Aging 2007:2(4) 506
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demonstrated that in the PTH/HRT group, BMD continued 
to increase at the vertebra measured by qCT and DXA (46% 
and 12.6% respectively) (Lane et al 2000). BMD also con-
tinued to increase at the hip attaining a 4.7% increase at the 
total hip and a 5.2% increase at the femoral neck. There was 
no signiﬁ  cant change in the HRT-alone group during the 12 
months of additional follow-up.
It should be noted that teriparatide is not approved for 
the treatment of GIO, and this would constitute off-label 
use of the medication. Although these early results are 
promising, more studies are needed to evaluate the efﬁ  cacy 
of PTH in younger patients and when used as a single agent. 
Nonetheless, in patients with GIO who do not respond to, 
or cannot tolerate bisphosphonates, PTH is an alternative 
worth consideration.
Side-effects, exclusion criteria,
and toxicity
PTH injections, as one might expect, do have some effect 
on serum calcium levels. The phase III trial demonstrated 
that teriparatide levels reached a maximum within an hour 
and returned to baseline after 4 hours (Neer et al 2001). 
Serum calcium peaked approximately 4 hours after injec-
tion, but the increase was mild (0.8 mg/dL) and total calcium 
remained within the normal range in almost all subjects. Only 
3% of patients required a calcium-based dose reduction in 
teriparatide. One-tenth of 1% of subjects withdrew because 
of increased calcium levels. Hypercalciuria was increased 
slightly, and 3% of patients had a signiﬁ  cant increase in uric 
acid resulting in overt gout in several patients. Dizziness and 
leg cramps were associated with injection, and reported in 9% 
and 3% of patients respectively, statistically more than in the 
placebo group. Although the incidence of osteosarcoma was 
increased in animal trials involving rats, osteosarcoma has 
not been observed in human trials. The bone morphology 
changes induced in rats was highly abnormal, with gross 
overgrowth of bone almost to the obliteration of the marrow 
space (Vahle et al 2002). Nonetheless, the FDA placed a 
black box warning on the drug insert and all patients should 
be made aware of this prior to initiating therapy.
Teriparatide cannot be used in pediatric patients, patients 
who have Paget’s disease, prior radiation to the bones, bone 
metastasis, pre-existing hypercalcemia, pregnancy, or meta-
bolic bone disease other than osteoporosis.
Conclusions
Teriparatide is well-tolerated with few side effects, although 
daily subcutaneous injections and cost remain impediments 
to adoption in practice. There is substantial evidence that 
teriparatide functions as an anabolic agent with the induction 
of new bone formation that is structurally similar to normal 
bone. Teriparatide increases BMD, and reduces the risk of 
vertebral fracture and hip fracture. Concomitant or prior 
use of alendronate, but not raloxifene or estrogen, blunts 
the effects of teriparatide. The optimal alendronate holiday 
prior to instituting teriparatide is unknown, but probably 
will be at least 6 months. An antiresorptive should be added 
after a course of teriparatide is completed to prevent loss 
of BMD.
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